Novelstem International Corp
novelstem.comWhat Do They Do?
Holds rights to profits from licensing stem-cell technology for cancer drug discovery and diagnostics.
10-K for FY2025, filed Mar 26, 2026NovelStem International Corp. (“NovelStem” or the “Company”) is a holding company whose principal assets consisted of an approximate 31%…View ↗
During the third quarter of 2024, it became evident that NewStem would not be able to raise funds to continue operations consisting of…View ↗
NewStem was a development stage Israeli biotech limited liability company that performed research focused on human Pluripotent Stem Cells…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$85.8KView ↗
- ▼ Now a loss
- vs $2.8M in Q2 FY2025
From biotech holding to license rights
The older report describes NovelStem as focused on NewStem’s stem-cell research and development; the latest describes rights to profits from the license after NewStem’s liquidation.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 26, 2026
NetCo interest sold
The older report describes NetCo as a joint venture holding entertainment rights and distributing proceeds; the latest says NovelStem sold its interest to its joint-venture partner.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 26, 2026
Loading...
